試す - 無料

'AI stocks may correct but 2000-style crash unlikely'

Business Standard

|

November 20, 2025

US smallcaps are a compelling value opportunity amid concerns about stretched valuations in artificial intelligence-linked stocks, says Vincent Nichols, investment specialist, US and thematic equity, at BNP Paribas Asset Management. The firm's GIFT City venture has launched the Baroda BNP Paribas GIFT US Small Cap Fund, a feeder fund. Nichols, in an interview with Samie Modak in ‘Mumbai, says US smallcaps — which have trailed largecaps through a prolonged earnings recession — are now seeing profits bottom out. Valuations are more attractive than those of largecaps. Edited excerpts:

- Vincent Nichols

The US market has been doing well, largely driven by big tech. Do you see this continuing, or do you think the market has entered an expensive territory?

There are two parts to that question. Regarding valuation, yes, by many metrics, the market looks rich. But that doesn’t mean underperformance is imminent. Valuation is a poor predictor of near-term returns. As long as mega-cap tech companies continue investing heavily in capex and AI infrastructure, I expect the momentum to continue. There could be short-term corrections technically but a bubble burst like in 2000 seems unlikely. These companies invest in Al because it’s existential to their businesses, not solely for attractive returns. I believe the strength in tech could last a couple more years.

Al has become a crowded trade globally. Is there still money flowing to this space?

While it is a crowded trade, ironically, we aren’t seeing much new money flowing into it recently. Many investors already have large positions in US tech, mostly via passive or active management. Even our team has not seen significant inflows. Globally, there’s been pessimism about the US investment story but the market has proven resilient.

You talked of the dotcom bubble. How is the scenario different now?

Business Standard からのその他のストーリー

Business Standard

Labour Codes impact: HCL tech profit slips 11%

Q3 top line beats Street estimates, bottom line misses expectations

time to read

2 mins

January 13, 2026

Business Standard

New labour Codes, restructuring weigh on TCS earnings

Tata Consultancy Services (TCS), India’s largest information technology (IT) services firm, saw its profit impacted in the October-December quarter by restructuring and changes in labour Codes.

time to read

1 min

January 13, 2026

Business Standard

Business Standard

Black drives the thrill for car buyers

Sees a surge in yearly sales, while white remains practical 'utility king'

time to read

2 mins

January 13, 2026

Business Standard

CHOOSING THE RIGHT B-SCHOOL TO MATCH YOUR CAREER GOALS

Success comes when you pick an institution that fits your professional dreams and your personality, helping you become the leader you want to be

time to read

2 mins

January 13, 2026

Business Standard

Business Standard

China’s PVC rethink to help India pipe makers

Supply likely to tighten after S-PVC rebate withdrawal

time to read

2 mins

January 13, 2026

Business Standard

Responsible growth

India must ensure data centres are sustainable

time to read

2 mins

January 13, 2026

Business Standard

India’s GenZ is full of creativity: PM

Prime Minister Narendra Modi on Monday said India's GenZ is full of creativity and with innovative ideas, energy and purpose, the country’s youth is at the forefront of nation-building.

time to read

1 min

January 13, 2026

Business Standard

Business Standard

Iran wants to negotiate after threats to attack, says Trump

At least 572 killed in protests; Tehran says situation ‘under full control’

time to read

2 mins

January 13, 2026

Business Standard

Insurers knock on Irdai door for clarity on director overlap ban

CLAUSE THREATENS BOARD STRUCTURES AT BANK-BACKED FIRMS SAYS INDUSTRY

time to read

2 mins

January 13, 2026

Business Standard

Delhi HC allows Zydus to sell generic version of cancer drug

Citing public interest, the Delhi High Court has cleared the way for Zydus Life-sciences to proceed with the sale of its version of the cancer drug nivolumab in India.

time to read

1 min

January 13, 2026

Listen

Translate

Share

-
+

Change font size